The story presents a conundrum. Plaintiffs file a class action, which the defendant initially resists. Plaintiffs counsel spends hundreds of thousands of dollars (or more) in lodestar and costs ...
On Wednesday, Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) entered into a settlement agreement with Teva Pharmaceuticals Industries Ltd (NYSE:TEVA). This Agreement resolves the patent litigation ...
NEW YORK--(BUSINESS WIRE)-- Marsh, the world’s leading insurance broker and risk adviser, today announced the inaugural class of cybersecurity solutions receiving a Cyber Catalyst SM designation as ...
Teva cannot market its generic version of Firdapse in the U.S. before February 25, 2035, unless specific conditions arise. Ongoing Firdapse patent litigation continues against Hetero and Lupin, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback